Royal Bank Of Canada Kintara Therapeutics, Inc. Transaction History

Royal Bank Of Canada

  • $425 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$0.82 - $2.3 $410 - $1,150
-500 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$1.26 - $2.4 $630 - $1,200
500 New
500 $1,000

About Kintara Therapeutics, Inc.

KTRA Quotes by TradingView
  • Ticker KTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,807,296
  • Market Cap $17.8M
  • Description
  • Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...
More about KTRA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email